Syngen Biotech Co., Ltd. (8279) AI Stock Analysis

Syngen Biotech Co., Ltd.

(TPEx:8279)

Select Model

Rating:70Outperform

Price Target:TWD 88.00▲(8.78% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported primarily by the strong balance sheet, positive cash generation, and attractive valuation. These strengths are tempered by declining revenue and margins and by weak positioning relative to longer-term moving averages.

Positive Factors

Improving Balance SheetThe sharp reduction in leverage gives Syngen greater financial flexibility and lowers balance-sheet risk as it funds ongoing operations. Steadily growing equity provides a stronger capital base, improving resilience and preserving capacity for investment through normal business cycles.

Negative Factors

Uneven Cash GenerationCash conversion below net income means reported profitability is not consistently translating into cash available for reinvestment or distribution. The 2025 free-cash-flow decline adds concern that working-capital or reinvestment demands could continue to constrain financial flexibility.

Syngen Biotech Co., Ltd. (8279) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 2.18B
Dividend Yield: 6.18%
Average Volume (3M): 41.18K
Price to Earnings (P/E): 10.7
Beta (1Y): 0.20
Revenue Growth: -3.92%
EPS Growth: -29.93%
Country: TW
Employees: 554
Sector: General
Sector Strength: 55
Industry: Biotechnology

Syngen Biotech Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 1988 and based in Tainan City, Taiwan, Syngen Biotech Co.,Ltd. operates globally, including in Taiwan and China, specializing in the research, development, production, and sale of a diverse array of products. Its core offerings include...

Syngen Biotech Co., Ltd. Financial Statement Overview

Summary

Strong balance sheet and improving cash generation support the score, but the 24.7% TTM revenue decline, lower margins, and reduced return on equity are meaningful weaknesses.

Income Statement

55Neutral

Balance Sheet

88Very Positive

Cash Flow

76Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.05B	2.14B	2.01B	1.84B	1.93B	1.47B
Gross Profit	635.67M	723.59M	723.94M	643.92M	688.15M	528.34M
EBITDA	305.85M	448.31M	423.57M	442.14M	448.88M	380.42M
Net Income	204.72M	271.59M	240.21M	274.83M	321.24M	237.77M
Balance Sheet
Total Assets	3.14B	3.05B	3.08B	3.11B	3.07B	2.42B
Cash, Cash Equivalents and Short-Term Investments	322.49M	275.46M	341.93M	366.89M	246.05M	314.80M
Total Debt	338.68M	315.59M	544.80M	681.76M	786.53M	236.08M
Total Liabilities	735.85M	674.89M	848.52M	974.63M	1.08B	644.16M
Stockholders Equity	2.40B	2.37B	2.24B	2.13B	1.99B	1.77B
Cash Flow
Free Cash Flow	319.45M	243.07M	283.70M	321.33M	-307.23M	274.83M
Operating Cash Flow	401.93M	319.48M	348.04M	415.13M	277.48M	336.50M
Investing Cash Flow	-82.75M	-76.83M	-84.53M	-93.68M	-585.05M	-336.07M
Financing Cash Flow	-280.34M	-309.47M	-289.09M	-200.54M	238.75M	-108.88M

Syngen Biotech Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:8279 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:8432	85Outperform	TWD 2.36B	11.30	―	4.22%	20.56%	67.85%
TW:8279	70Outperform	TWD 2.21B	10.69	―	6.18%	-3.92%	-29.93%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4108	47Neutral	TWD 2.06B	-48.44	―	―	1.10%	54.83%

* General Sector Average

Performance Comparison

TW:8279 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:8279	Syngen Biotech Co., Ltd.	80.90	-42.26	-34.31%
TW:4108	Phytohealth Corporation	10.40	-3.90	-27.27%
TW:6932	Merdury Biopharmaceutical Corporation	5.23	-4.87	-48.22%
TW:7731	MARX Biotech Co., Ltd.	4.26	-0.95	-18.25%
TW:7860	Teh Seng Pharmaceutical Mfg Co Ltd	77.80	2.28	3.01%
TW:8432	TSH Biopharm Corp. Ltd.	61.90	9.79	18.80%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Syngen Biotech Co., Ltd. AI Stock Analysis